Next Article in Journal
Re: Countercurrents: Is Now the Right Time to Pull the Plug on Mammography?
Previous Article in Journal
African–Caribbean Cancer Consortium Scientific and Training Conference 2017
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 6
10.3747/co.26.4845
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Letter

Multiplicity and the Marginal Benefits of Bevacizumab in Malignant Solid Tumours

by
Vinay Prasad
Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
Curr. Oncol. 2019, 26(6), 791-792; https://doi.org/10.3747/co.26.4845
Submission received: 11 September 2019 / Revised: 7 October 2019 / Accepted: 5 November 2019 / Published: 1 December 2019

Abstract

Although clinical trials of novel medications have historically been individually interpreted, there is increasing recognition that trials should be considered to be part of a broader clinical trials agenda or portfolio […]

Share and Cite

MDPI and ACS Style

Prasad, V. Multiplicity and the Marginal Benefits of Bevacizumab in Malignant Solid Tumours. Curr. Oncol. 2019, 26, 791-792. https://doi.org/10.3747/co.26.4845

AMA Style

Prasad V. Multiplicity and the Marginal Benefits of Bevacizumab in Malignant Solid Tumours. Current Oncology. 2019; 26(6):791-792. https://doi.org/10.3747/co.26.4845

Chicago/Turabian Style

Prasad, Vinay. 2019. "Multiplicity and the Marginal Benefits of Bevacizumab in Malignant Solid Tumours" Current Oncology 26, no. 6: 791-792. https://doi.org/10.3747/co.26.4845

APA Style

Prasad, V. (2019). Multiplicity and the Marginal Benefits of Bevacizumab in Malignant Solid Tumours. Current Oncology, 26(6), 791-792. https://doi.org/10.3747/co.26.4845

Article Metrics

Back to TopTop